Report Highlights
The total market for pandemic infectious disease products broken down by disease type was $31.6 billion in 2011 and $35.6 billion in 2012. The market is expected to rise at a CAGR of 9.3% and reach nearly $55.6 billion by 2017.
The report provides:
- An overview of the products in development to treat bacterial diseases, especially those caused by drug-resistant organisms, and HIV/AIDS
- Analyses of market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Clarification of the HIV/AIDS pandemic and ongoing efforts to control it
- Discussion of emerging threats, such as multidrug-resistant tuberculosis, West Nile virus and other serious viral diseases
- Trends based on projected sales through 2017 for new products, including supporting analyses for projections.
- Comprehensive company profiles of major players.
Report Scope
This report provides an in-depth look at the emerging pandemic of antibiotic resistance and the established viral pandemic of HIV/AIDS. It also provides historical, epidemiological and market information on hepatitis B and C, tuberculosis and malaria. This report also investigates bacterial and viral diseases that are emerging as health threats because of inadequate or nonexistent preventive and/or therapeutic products to combat them.
Antibiotic-resistant organisms wreak havoc with international healthcare systems as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE) and Clostridium difficile (C. diffile) become more pervasive. These infections represent future pandemics if no suitable antibiotics are developed to counteract them. At present, each is problematic, but remains at an epidemic level, primarily within healthcare institutions and nursing facilities. Consequently, these infections are covered descriptively within the report, but are not yet classified as pandemics, nor measured quantitatively as part of the overall market for pandemics.
The report outlines the available preventative and diagnostic products used to combat current and future pandemic infections and projects markets for these products. Forecasts are provided for the diagnostic and pharmaceutical markets for products to treat HIV/AIDS, hepatitis B and C, malaria and tuberculosis. Forecasts and trends are gleaned from industry sources as well as from an assessment of emerging products and technologies.
The causes, the extent of impact and strategies to monitor, treat and prevent resistant diseases are assessed. The mechanisms by which drugs function to combat resistant microbes are described. Drugs that show promise of long-term activity (i.e., low likelihood of resistance) and their effects on the market are assessed.
Analyst Credentials
Peggy S. Lehr is the BCC Research analyst of this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder, and a MS in Communication from the University of Denver. Ms. Lehr has worked as a researcher, editor and publisher within the publishing industry for both for-profit and not-for-profit organizations.
Related Reports
Global Markets for Infectious Disease Treatments
The global market for infectious disease diagnostic, vaccine and pharmaceutical products was $59.2 billion in 2011 and $66.4 billion in 2012. Market growth looks promising, the overall market value for 2017 is projected to be $96.8 billion after increasing at a compound annual growth rate (CAGR) of 7.8%.
Antibody Drugs: Technologies and Global Markets
The global market for therapeutic monoclonal antibodies (mAbs) was estimated at $44.6 billion in 2011. With the rollout of at least eight new therapeutic mAb products and expanded indications for existing products expected during the forecast period, the global mAb market is expected to rise at a compound annual growth rate (CAGR) of 5.3% to nearly $58 billion in 2016.
Drugs and Treatments for Autoimmune Diseases: Global Markets
The global market for autoimmune treatments reached at $34 billion in 2010, it is expected to reach at $38.9 billion by 2011 and it will further grow to $55 billion by 2016 at a compounded annual growth rate (CAGR) of 7.2%.
Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products
The global market for healthcare-acquired infection treatments were nearly $16 billion in year 2010. This market is estimated to be around $18.3 billion in the year 2011 and is forecasted to reach $25.6 billion by 2016 at a CAGR of 7.0% for five year period.
Track the Latest Global Tariff Developments
In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.
Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.
Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.
With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.
Ready to see what tariff means for your business?
Consult with our experts or request your custom Tariff Impact Brife today
Stay Informed, Stay Competitive
In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.
Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.
Our analysis includes:
- Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
- Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
- Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.
With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.
Don't let tariffs catch you off guard—let our insights guide your strategy.
Recent Reports
Anti-Parkinson's Drugs: Global Markets to 2030
The global market for anti-Parkinson’s drugs is projected to grow from $6.1 billion in 2025 to reach $9.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030.
Global Markets for Infectious Disease Treatments
The global market for infectious disease treatments is expected to grow from $72.5 billion in 2025 and is projected to reach $101 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.9% during the forecast period of 2025 to 2030.
Disease-Modifying Therapies for Alzheimer’s Disease: Global Markets
This report provides an overview of the global and regional markets for disease-modifying therapies for Alzheimer’s disease. It includes global revenue ($ million) for base year data of 2024, estimates for 2025, and CAGR forecasts through 2030.
Global Markets for Allergy Diagnostics and Treatments
The global market for allergy diagnostics and treatment is projected to grow from $67.8 billion in 2025 to $96.4 billion by the end of 2030, at a compound annual rate growth (CAGR) of 7.3% from 2025 through 2030.
Over-the-Counter (OTC) Drugs, and Vitamins & Dietary Supplements: Global Markets
The global market for over-the- counter (OTC) drugs, vitamins and dietary supplements is expected to grow from $276.9 billion in 2025 and is projected to reach $371.7 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.1% during the forecast period of 2025 to 2030.
Report Highlights
-
The market for "new antibiotics" and HIV/AIDS treatments was $6.2 billion in 2003 and is rising at an AAGR (average annual growth rate) of 9.1%. It is expected to reach $10.1 billion in 2008.
-
New antibiotics (products introduced in 2000 or later) will move from a market share of just under 4% in 2003 to a projected market share of more than 20% in 2008, rising at an AAGR of nearly 34%.
-
Drugs to treat HIV/AIDS will not see as dramatic an annual growth rate, but will continue to expand at a healthy pace as a result of recently introduced products.
-
In this category, combination products are taking market share away from single-chemical agents, and this trend will continue throughout the forecast period.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More